reference/14762683

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14762683

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	43
issn	1464-4096 1464-410X
issueIdentifier	5b
pageRange	E137-43
publicationName	BJU International
startingPage	E137
bibliographicCitation	Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014 May;113(5b):E137–43. doi: 10.1111/bju.12564. PMID: 24219029.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d8a058f88ce52d67ced98757d70380b7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d0dc16b753edf47604a5b7a2d5aff5e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cb7b7d10d298acf2d0125fd8db3dfff6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc81a9776093c619770d3a6f8ec0a0e9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb732232bd3979e492c22e03000c2c5b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_78a22c4222a20a56f6f578e19047f704 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b52e34f9349a5bc7fb9f45e5cc5153a2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_58a0cd26a2e97d3133688f12df5d9648 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27e288f6fe267284d8550117536eb7b4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4016a9d4414543de01e13cf62307009e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d49d6b1c0c8b5e3101075fb27915a95d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_638ae528cd37095b12cff446ae0a9273 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_11005dda5c275957caeae81cb9d4bb66 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff1be1040b7eaf55c1369e18afbed931 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76045bd6c899f64ce94bbf4abc1c7b58 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_20334672392b7db731410a3562f89d66 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-6929-8691 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b13a05ef34fc0c5949c283d11809982f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31b45ac1d926059b9545179907316143 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_20421d8ab0f34827712d7edebc0ede59 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7f8157cea427403faf15dbb129b91e79 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3007-2756 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a12d67aec3949b17cfc331c5fbb1672 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3ec634d14ed50ed027d1b4b90f260e33 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_acea6d964074c703e7e960a53e740bdf
date	2014-04-23^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/24219029 https://doi.org/10.1111/bju.12564
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21363 https://portal.issn.org/resource/ISSN/1464-410X https://portal.issn.org/resource/ISSN/1464-4096
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D049451 http://id.nlm.nih.gov/mesh/D002295Q000188 http://id.nlm.nih.gov/mesh/D014571Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D002295Q000556 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D014571Q000473 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008113Q000556
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8352 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7173

Showing number of triples: 1 to 61 of 61.